Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
- Once an individual becomes eligible, they remain eligible until their 80th birthday
- Adults who are severely immuncompromised aged 50 or over are eligible with no upper age limit
- SHINGRIX is given as a 2 dose schedule. The GreenBook guidance for administration of the second dose as part of the national immunisation programme differs from the SmPC
Are you aware of the changes to the Shingles National Immunisation Programme?
Are you effectively implementing the Shingles National Immunisation Programme? View our implementation hub
Shingles is a painful disease that can have serious and long-lasting complications2
Prescribing information (GB)
Prescribing information (NI)
Summary of product characteristics (GB)
Summary of product characteristics (NI)
References
- The GreenBook chapter 28a – Shingles. July 2023
- UK NICE Clinical Knowledge Summaries (Shingles) August 2021
- SHINGRIX. Summary of Product Characteristics (GB)
- SHINGRIX. Summary of Product Characteristics (NI)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
December 2023 | PM-GB-SGX-WCNT-230004 (V3.0)
